Shots:
- Gilead Sciences has exercised its option to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader, from Kymera Therapeutics under their existing collaboration
- The option exercise triggers a $45M milestone payment to Kymera; the company remains eligible for up to $750M in total payments, including milestones and tiered royalties on net sales
- Gilead will advance KT-200 into IND-enabling studies with a planned IND filing in 2027; preclinical data demonstrated potent CDK2 degradation, anti-tumor activity in CCNE1-amplified models, and a favorable safety profile
Ref: Kymera Therapeutics | Image: Kymera Therapeutics | Press Release
Related News: Gilead to Acquire Tubulis for ~$5B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
